OTCPK:ENDV (USA)

Endonovo Therapeutics Inc

$ 0.01 0 (-0.98%)
Volume: 5,674,042 Avg Vol (1m): 6,270,633
Market Cap $: 6.74 Mil Enterprise Value $: 13.03 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -0.01
Net Current Asset Value 0
Tangible Book -0.03
Projected FCF -0.07
Median P/S Value -0.24
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength :

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.01
Cash-To-Debt range over the past 10 years
Min: 0, Med: 0.02, Max: 10000
Current: 0.01
0
10000
Equity-to-Asset -3.09
Equity-to-Asset range over the past 10 years
Min: -102.02, Med: -26.84, Max: -0.7
Current: -3.09
-102.02
-0.7
Debt-to-Equity -0.54
Debt-to-Equity range over the past 10 years
Min: -2.61, Med: -0.26, Max: -0.15
Current: -0.54
-2.61
-0.15
Debt-to-EBITDA -1.35
Debt-to-EBITDA range over the past 10 years
Min: -1.35, Med: 0, Max: 0
Current: -1.35
-1.35
0
Beneish M-Score -18.80
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 45.82%

Profitability & Growth :

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Net Margin % 177.03
Net Margin range over the past 10 years
Min: -1158.17, Med: 256.41, Max: 1679.82
Current: 177.03
-1158.17
1679.82
ROA % -191.46
ROA range over the past 10 years
Min: -3806.58, Med: -438.45, Max: -16.18
Current: -191.46
-3806.58
-16.18
3-Year Total Revenue Growth Rate -17.70
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -46.55, Max: 59.3
Current: 24.1
0
59.3
3-Year EPS w/o NRI Growth Rate 34.10
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -25.6, Med: 54.05, Max: 76.7
Current: 34.1
-25.6
76.7

» ENDV's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:ENDV

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XSAT:INIT ASX:1AD OTCPK:PNTV ASX:ATH OTCPK:QRON ASX:PIQ OTCPK:CLCS ASX:LCT AMEX:IBIO NAS:OTLK OTCPK:AMAR ROCO:6236 NAS:GNMX NAS:XBIO ASX:ANR OCSE:NEUR LSE:IXI TSXV:HEM ASX:RGS ASX:KZA
Traded in other countries
Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is a US-based biotechnology company which focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.

Ratios

Current vs industry vs history
EV-to-Revenue -2.31
EV-to-Revenue range over the past 10 years
Min: 7.2, Med: 15.6, Max: 29.7
Current: -2.31
7.2
29.7

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -51.20
3-Year Share Buyback Rate range over the past 10 years
Min: -1118.6, Med: -299.7, Max: -51.2
Current: -51.2
-1118.6
-51.2

Valuation & Return

Current vs industry vs history

More Statistics

Revenue (TTM) (Mil) $ -4.65
EPS (TTM) $ -0.03
Beta 2.65
Volatility % 123.87
52-Week Range $ 0.01 - 0.07
Shares Outstanding (Mil) 558.16

Analyst Estimate

Piotroski F-Score Details